Valuation: MetaVia Inc.

Market Cap 7.49M 6.5M 6.08M 5.57M 10.51M 713M 10.65M 71.19M 27.94M 356M 28.12M 27.5M 1.19B P/E 2026 *
-0.58x
P/E 2027 * -0.6x
Enterprise Value 7.49M 6.5M 6.08M 5.57M 10.51M 713M 10.65M 71.19M 27.94M 356M 28.12M 27.5M 1.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
63.5%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week+0.69%
Current month+2.11%
1 month-3.97%
3 months+3.57%
6 months-20.33%
Current year-82.78%
1 week 1.44
Extreme 1.44
1.56
1 month 1.38
Extreme 1.38
2.61
Current year 0.97
Extreme 0.9661
9.61
1 year 0.97
Extreme 0.9661
19.03
3 years 0.97
Extreme 0.9661
74.25
5 years 0.97
Extreme 0.9661
13,068.01
10 years 0.97
Extreme 0.9661
79,200.08
Manager TitleAgeSince
Chief Executive Officer 50 11/08/2023
Director of Finance/CFO 68 27/10/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 55 31/12/2019
Director/Board Member 76 31/12/2019
Director/Board Member 50 09/07/2021
Date Insider Type Main position Quantity % Market Cap.
1/23/26 A Free

Chief Executive Officer

32,000 1.3913%
1/23/26 A Free

Chief Financial Officer

28,000 1.2174%
8/12/25 A Don

Chief Financial Officer

14,200 0.0725%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%+0.69%-78.65%-97.00% 7.49M
-3.25%+13.72%+52.49%+88.86% 62.92B
+2.36%+3.60%+34.04%+74.58% 54.32B
-1.07%-1.79%-18.07%-14.36% 22.91B
+33.86%+30.60%+19.14%+502.77% 28.73B
+10.83%+18.38%+52.76%+4.58% 21.65B
+8.92%+9.98%+41.31%-19.56% 17.76B
-3.37%+25.85%+213.21%+369.13% 16.47B
+6.20%+11.51%+34.94%+681.88% 15.48B
-7.94%-6.74%+38.42%+157.52% 13.12B
Average +4.39%+7.34%+38.96%+174.84% 25.34B
Weighted average by Cap. +4.75%+8.61%+46.26%+166.60%

Financials

2026 *2027 *
Net sales - -
Net income -18.05M -15.66M -14.67M -13.42M -25.33M -1.72B -25.66M -172M -67.34M -859M -67.77M -66.29M -2.86B -27.58M -23.94M -22.41M -20.5M -38.71M -2.63B -39.21M -262M -103M -1.31B -104M -101M -4.37B
Net Debt - -
Logo MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Employees
8
Date Price Change Volume
06/08/26 $1.450 -2.68% 37,439
05/08/26 $1.490 +2.05% 46,953
04/08/26 $1.460 -1.35% 64,229
03/08/26 $1.480 +4.23% 35,364
31/07/26 $1.420 -1.39% 133,201
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.450USD
Average target price
19.33USD
Spread / Average Target
+1,233.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTVA Stock